Your browser doesn't support javascript.
loading
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial.
Ciruelos, Eva; Villagrasa, Patricia; Pascual, Tomás; Oliveira, Mafalda; Pernas, Sonia; Paré, Laia; Escrivá-de-Romaní, Santiago; Manso, Luis; Adamo, Barbara; Martínez, Eduardo; Cortés, Javier; Vazquez, Silvia; Perelló, Antonia; Garau, Isabel; Melé, Mireia; Martínez, Noelia; Montaño, Alvaro; Bermejo, Begoña; Morales, Serafin; Echarri, María J; Vega, Estela; González-Farré, Blanca; Martínez, Débora; Galván, Patricia; Canes, Jordi; Nuciforo, Paolo; Gonzalez, Xavier; Prat, Aleix.
Afiliação
  • Ciruelos E; Hospital Universitario 12 de Octubre, Madrid, Spain. eva.ciruelos@gmail.com alprat@clinic.cat.
  • Villagrasa P; Centro Integral Oncológico Clara Campal HM (CIOCC), Madrid, Spain.
  • Pascual T; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Oliveira M; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Pernas S; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Paré L; Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Escrivá-de-Romaní S; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Manso L; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Adamo B; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Martínez E; Vall d' Hebron University Hospital, Barcelona, Spain.
  • Cortés J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Vazquez S; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Perelló A; Institut Català d'Oncologia, Hospitalet del Llobregat, Spain.
  • Garau I; SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Melé M; Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Martínez N; Vall d' Hebron University Hospital, Barcelona, Spain.
  • Montaño A; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Bermejo B; Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Morales S; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Echarri MJ; Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Spain.
  • Vega E; IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain.
  • González-Farré B; Institut Català d'Oncologia, Hospitalet del Llobregat, Spain.
  • Martínez D; Hospital Universitari Son Espases, Palma de Mallorca, Spain.
  • Galván P; Hospital Son Llàtzer, Palma de Mallorca, Spain.
  • Canes J; Hospital Universitari Sant Joan de Reus, Reus, Spain.
  • Nuciforo P; Hospital Universitario Ramon y Cajal, Madrid, Spain.
  • Gonzalez X; Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Prat A; Hospital Clínico Universitario de Valencia, Valencia, Spain.
Clin Cancer Res ; 26(22): 5820-5829, 2020 11 15.
Article em En | MEDLINE | ID: mdl-32938620
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Piridinas / Neoplasias da Mama / Receptor ErbB-2 / Trastuzumab Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Piridinas / Neoplasias da Mama / Receptor ErbB-2 / Trastuzumab Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Ano de publicação: 2020 Tipo de documento: Article